Technology | BNP Platform
Historically there have been varying delivery methods and vehicles used in the attempt to safely deliver therapeutic genes. The use of viruses, called viral vectors, takes advantage of a viruses' natural ability to introduce DNA to cells. Due to its non-pathogenic properties, its ability to maintain efficient and long-term expression, and its ease of genetic manipulation, recombinant adeno-associated virus (rAAV) has quickly become the gene-delivery vector of choice for a multitude of targets.
Asklepios BioPharmaceutical Inc (Askbio) has exclusively licensed and developed a platform technology related to AAV vectors for efficient long-term transgene delivery. This platform is utilized by Askbio for an internal pipeline in a clinical development capacity, as well as generating licensing opportunities within the gene and RNAi delivery field. Askbio has executed agreements with Baxter, GSK, Pfizer, Bayer, Merck & Medtronic to further develop this platform. The technologies being developed by Askbio offer unique advantages over other existing approaches to nucleic acid delivery, and include discoveries (now reduced to practice) relating to the vector genome structure, the packaging of vector genomes into various capsids, the physiological characteristics of the vector surface structures, as well as methods for production and delivery of vectors.
Asklepios BioPharmaceutical, Inc., has developed a library of rAAV Biological Nano Particles (BNPTM), a next generation gene delivery platform technology. These synthetically designed particles provide unsurpassed transduction efficiency, "ramp-up" expression capabilities, with novel tissue targeting and de-targeting properties. The proprietary rAAV BNPTM technology combined with the company's complementary enabling technologies, poises Asklepios as the company to bridge the current technical gap of reliable, safe, and efficient nucleic acid delivery delivery.